Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine
- 13 May 2016
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Neurotherapeutics
- Vol. 16 (7), 777-793
- https://doi.org/10.1080/14737175.2016.1181543
Abstract
Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.Keywords
This publication has 100 references indexed in Scilit:
- Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosisNeuroImage: Clinical, 2014
- Inflammatory Cortical Demyelination in Early Multiple SclerosisThe New England Journal of Medicine, 2011
- A Bayesian model of shape and appearance for subcortical brain segmentationNeuroImage, 2011
- Association of matrix metalloproteinases with MRI indices of brain ischemia and agingNeurobiology of Aging, 2010
- Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume changeNeuroImage, 2010
- Genetic Ancestry Is Associated With Subclinical Cardiovascular Disease in African-Americans and Hispanics From the Multi-Ethnic Study of AtherosclerosisCirculation: Cardiovascular Genetics, 2009
- Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measuresBrain, 2009
- Cognitive impairment in relapsing—remitting multiple sclerosis can be predicted by imaging performed several years earlierMultiple Sclerosis Journal, 2007